Epilepsy

An abnormal composite outcome of death or disability at age 18 to 22 months was found in 46% of those who had seizures during rewarming compared with 25% of those without seizures at rewarming.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 29, 2021.

Here's what is coming soon to NeurologyLive.

Neurology News Network for the week ending October 23, 2021. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 22, 2021.

Just about two-thirds of patients remained on cenobamate throughout the entire analysis period and almost 40% had complete seizure reduction for at least 12 consecutive months at some time during the study.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 15, 2021.

The registered dietitian at Ann & Robert H. Lurie Children’s Hospital of Chicago provided knowledge on the how and why diets are constructed for patients with epilepsy.

The registered dietitian at Ann & Robert H. Lurie Children’s Hospital discussed the unknowns in terms of managing and prescribing diets for patients with epilepsy. [WATCH TIME 3 minutes]

Here's what is coming soon to NeurologyLive.

The division chief of vascular neurology at the University of Utah discussed the individual role that clinicians and neurologists can play to increase interest in the field of neurology. [WATCH TIME: 2 minutes]

Neurology News Network for the week ending October 9, 2021. [WATCH TIME: 3 minutes]

Preclinical results showed promise for the investigational formulation in reducing seizures, prompting the patent filing.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 8, 2021.

The registered dietician at Ann & Robert H. Lurie Children’s Hospital of Chicago provided insight on the importance of educating youths with epilepsy on diets, especially in the transition stages of care. [WATCH TIME: 2 minutes]

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive team.

Monthly focal seizure frequency was reduced from baseline at all 3 dose levels of the differentiated Kv7 potassium channel modulator, compared to placebo.

Data from 31,052 patients on the German Multiple Sclerosis Register were analyzed in the case-control study.

The registered dietician at Ann & Robert H. Lurie Children’s Hospital of Chicago discussed whether epilepsy type factors into the decision to use a given dietary approach. [WATCH TIME 2 minutes]

The registered dietician at Ann & Robert H. Lurie Children’s Hospital of Chicago provided commentary on the multidisciplinary efforts to tailor a patient’s diet. [WATCH TIME: 3 minutes]

Differences in response to treatment with levetiracetam (Keppra; UCB Pharma) among individuals with and without epileptiform activity who have Alzheimer disease warrant future investigations of other antiseizure medications in this population, according to study authors.

Here's what is coming soon to NeurologyLive.

After 10-12 months of treatment, 51.2% of patients responded with a clinically meaningful reduction in drop seizures, while 25.3% of patients demonstrated a profound reduction.